Similarly, other studies characterizing non-muscle-invasive and muscle-invasive high-grade urothelial carcinoma reported similar incidence of FGFR-3 mutations, ranging from 11% to 52% suggesting that the rate of FGFR-3 mutations may vary significantly depending on the methods used, site of assessment and variants of urothelial carcinoma included in the studies [26,27,28,29] (Table 4). This evidence concerns the gene FGFR3 and urothelial carcinoma.